Pharmaceutical - Oncology

Filter

Current filters:

Oncology

Popular Filters

1 to 25 of 1223 results

NICE recommends another new skin cancer drug, GSK’s Tafinlar

22-10-2014

The UK National Institute for Health and Care Excellence (NICE) has issued final guidance recommending…

GlaxoSmithKlineOncologyPharmaceuticalPricingRegulationTafinlarUK

FDA fast-tracks Taiho Oncology’s TAS-102 for colorectal cancer

FDA fast-tracks Taiho Oncology’s TAS-102 for colorectal cancer

20-10-2014

The US Food and Drug Administration has granted Fast Track designation for TAS-102 (trifluridine and…

OncologyOtsukaPharmaceuticalRegulationTaiho OncologyTAS-102USA

Pharmacyclics files Imbruvica sNDA for Waldenstrom’s macroglobulinemia

20-10-2014

US drugmaker Pharmacyclics has submitted a supplemental New Drug Application to the US Food and Drug…

ImbruvicaJanssen BiotechJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsRegulationUSA

Pharmacyclics’ Imbruvica gains EU approval for two blood cancers

17-10-2014

US drugmaker Pharmacyclics has received marketing approval from the European Commission for Imbruvica…

EuropeImbruvicaJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsRegulation

Pharmacyclics and Roche research Imbruvica and Gazyva

Pharmacyclics and Roche research Imbruvica and Gazyva

17-10-2014

USA-based biopharma company Pharmacyclics has entered into a master clinical drug supply agreement with…

GazyvaImbruvicaOncologyPharmaceuticalPharmacyclicsResearchRocheUSA

NICE reverses guidance on Novartis’ Glivec for GIST

NICE reverses guidance on Novartis’ Glivec for GIST

17-10-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued new…

GlivecNovartisOncologyPharmaceuticalPricingRegulationUK

Strong new data for Novartis’ investigational leukemia drug CTL019

16-10-2014

Swiss pharma giant Novartis and the US University of Pennsylvania's Perelman School of Medicine (Penn)…

CTL019NovartisOncologyPharmaceuticalResearch

FDA grants priority reviews for Eisai's for rufinamide and lenvatinib

FDA grants priority reviews for Eisai's for rufinamide and lenvatinib

15-10-2014

There was good news for Japanese drugmaker Eisai yesterday, as the US Food and Drug Administration granted…

BanzelEisailenvatinibNeurologicalOncologyPharmaceuticalRegulationRufinamide TabletsUSA

WHO cancer agency launches new European Code Against Cancer

WHO cancer agency launches new European Code Against Cancer

14-10-2014

The specialized cancer agency of the World Health Organization, the International Agency for Research…

CancerEuropeHealthcareOncologyPharmaceutical

Pfizer’s palbociclib gains FDA Priority Review

13-10-2014

Pfizer says that the New Drug Application for its investigational breast cancer treatment palbociclib…

OncologypalbociclibPfizerPharmaceuticalRegulationUSA

FDA approves Eisai’s Akynzeo for CINV

13-10-2014

The US Food and Drug Administration has approved Japanese pharma major Eisai’s Akynzeo (netupitant…

AkynzeoEisaiHelsinnnetupitantOncologypalonosetronPharmaceuticalRegulationUSA

Positive Ph III results for Ipsen’s Decapeptyl in prostate cancer patients

12-10-2014

French drugmaker Ipsen has released positive results from the Phase III study of Decapeptyl (triptorelin…

DecapeptylIpsenOncologyPharmaceuticalResearch

Highlights from EMA Pharmacovigilance October meeting

10-10-2014

At its October meeting, the European Medicines Agency’ Pharmacovigilance Risk Assessment Committee…

Ariad PharmaceuticalsEuropeIclusigMen's HealthNeurologicalOncologyPharmaceuticalRegulationTestosteronevalproate

New Zealand approval of Novartis multiproduct proposal

10-10-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

NeurologicalNew ZealandOncologyPharmaceuticalRegulationRespiratory and Pulmonary

Oxford BioMedica enters LentiVector collaboration with Novartis

Oxford BioMedica enters LentiVector collaboration with Novartis

10-10-2014

UK-based Oxford BioMedica says that it has signed further contracts with Swiss pharma giant Novartis,…

GlobalLentiVectorLicensingMergers & AcquisitionsNovartisOncologyOxford BioMedicaPharmaceutical

Cancer care is advancing, but costs cannot be ignored, says UnitedHealthcare SVP

Cancer care is advancing, but costs cannot be ignored, says UnitedHealthcare SVP

09-10-2014

Cancer care is advancing, but policymakers and the cancer care community must find ways to make it more…

HealthcareOncologyPharmaceuticalPricingUSA

Nanobiotix to receive $1 million milestone after global trial expanded

Nanobiotix to receive $1 million milestone after global trial expanded

08-10-2014

French nanomedicine company Nanobiotix says that its partner PharmaEngine will join its pivotal trial…

Asia-PacificFranceNanobiotixNBTXR3OncologyPharmaceuticalPharmaEngineResearch

Drug development “failures” critical to discovery process, says new report

Drug development “failures” critical to discovery process, says new report

08-10-2014

US trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) has released a new report,…

OncologyPharmaceuticalPoliticsResearchUSA

PhRMA report outlines progress made into fighting cancer

PhRMA report outlines progress made into fighting cancer

07-10-2014

America's biopharmaceutical research companies are developing nearly 800 new medicines and vaccines for…

Manufacturers of AmericaOncologyPharmaceuticalResearchUSA

Teva to drop 14 pipeline projects as it refocuses

Teva to drop 14 pipeline projects as it refocuses

07-10-2014

Israeli generics giant Teva Pharmaceutical Industries has concluded an extensive evaluation of its current…

CopaxoneIsraelManagementNeurologicalOncologyPharmaceuticalRespiratory and PulmonaryTevaWomen's Health

Novartis and Bristol-Myers Squibb sign NSCLC collaboration

Novartis and Bristol-Myers Squibb sign NSCLC collaboration

07-10-2014

Swiss drug major Novartis and US peer Bristol-Myers Squibb have announced a clinical collaboration to…

Bristol-Myers SquibbNovartisOncologyOpdivoPharmaceuticalResearchUSAZykadia

Sunesis’ Phase III trial in AML fails to meet primary endpoint

Sunesis’ Phase III trial in AML fails to meet primary endpoint

07-10-2014

USA-based Sunesis Pharmaceuticals says that its pivotal Phase III trial of vosaroxin and cytarabine in…

CytarabineOncologyPharmaceuticalQinprezoResearchSunesis PharmaceuticalsUSAvosaroxin

Servier’s new research partnership with Walter and Eliza Hall Institute

Servier’s new research partnership with Walter and Eliza Hall Institute

04-10-2014

French independent pharma company Servier has established a collaborative partnership with Australia’s…

AustraliaFranceOncologyPharmaceuticalResearchServier

Roche could lose its dominant market share in breast cancer, says IMS report

Roche could lose its dominant market share in breast cancer, says IMS report

03-10-2014

Biosimilars and new generation agents will end the market dominance of established breast cancer drugs,…

AstraZenecaGlobalHerceptinMarkets & MarketingNovartisOncologyPharmaceuticalRochetamoxifen

1 to 25 of 1223 results

Back to top